UpdatesPlus Nicotinic Receptors - Current Research and Development - September 2009
Is your company active in the field of nicotinic therapeutics? Subscribe to UpdatesPlus now and keep up to date with events in this field and find out how your pipeline may be affected
Neuronal nicotinic receptor ligands are fast proceeding through clinical development as exciting candidates for multiple CNS disorders including Alzheimer's disease; Schizophrenia; ADHD; Depression; Pain and Addiction.
More recently we have been seeing the field expand with peripheral nicotinic receptors gaining increasing attention in relation to further indications including various inflammatory conditions and oncology
Are you involved in these areas; are you developing a nicotinic receptor ligand? If so UpdatesPlus is for you. This service, brought to you from the pharmaceutical analysts, LeadDiscovery, not only identifies all key breaking research, drug development news and clinical trials in this area, it also analyzes it.
Published monthly along with up to date pipelines, UpdatesPlus offers a key insight into strategy and development as well as new research advances. Offering an ideal intelligence tool for everyone from brand managers to medical directors and preclinical managers, UpdatesPlus is a must for all involved in this exciting new field of medicine. Well over half the companies involved in nicotinic receptors subscribe to UpdatesPlus. To see what you are missing open the free issue below
Table of Contents
What's in the September 2009 edition of UpdatesPlus-Nicotinic Receptors?
α7 nicotinic receptors
- What's coming up at Neuroscience/nACh2009
- 3 new preclinical candidates enter the α7 pipeline
- Abbott introduce candidate for Alzheimer’s disease
- J&J enters the nicotinics arena
- WYE-103914 to be introduced at Neuroscience
- Sanofi-aventis about to enter the clinic with CIAS candidate SAR130479?
- Further data presented to support the use of α7 as a strategy for reducing β-amyloid neurotoxicity
- α7 agonists as adjuncts to stem cell therapy
- Full and up to date α7 receptor pipeline
α4ß2 nicotinic receptors
- NeuroSearch’s collaborative program with Abbott has not been terminated
- Full and up to date α4β2 receptor pipeline
Smoking cessation - Nicotine addiction
- Full and up to date pipeline of smoking cessation therapeutics
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
2008 issues:
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September
- October
- November
- December
2009 issues:
- January 2009
- February 2009
- March 2009
- April 2009
- May 2009
- June 2009
- July 2009
- August 2009
Other users found this report page using the following search terms: Neuronal Nicotinic Receptors ABT-107 JNJ-1930942 WYE-103914 MEM 63908 R4996 ABT-107 TC-5619 EVP-6124 AZD-0328 SSR-180711 gts-21 MEM 3454 R3487 chantix champix Varenicline TC-6499 abt-560 AZD3480 TC-1734 tc-5214 ispronicline abt-894 ABT-089 nicotinic receptors cognition cognitive cias alzheimer amyloid depression smoking cessation alpha7 alpha6 alpha4beta2 nicotinic adhd alzheimers nicotine memory nicotinic receptors neuronal receptor varenicline champix chantix wellbutrin azd0328 sar130479 jnj1930942 current nicotine wye103914 2009 events nicotinic pipeline champix
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.